Novel combination therapy with imiquimod and tyrosine kinase inhibitor against renal cell carcinoma

• Project/Area Number: 15K10593
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kochi University
• Principal Investigator: KARASHIMA Takashi 高知大学, 教育研究部医療学系臨床医学部門, 准教授 (60304672)
• Co-Investigator(Kenkyū-buntansha): 執印 太郎 高知大学, その他部局等, その他(教授相当) (70128601)
• Co-Investigator(Renkei-kenkyūsha): KURODA Naoto 高知大学, その他の部局等, 客員教授 (60291457)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: 腎癌 / 免疫療法 / チロシンキナーゼ阻害剤 / 腎がん / イミキモド

Outline of Final Research Achievements

The specific aim of the study is to demonstrate a novel therapeutic strategy that can be applied clinically to a combination therapy with transdermal administration of Imiquimod as an immunoagent via Toll-like receptor 7 and oral administration of a tyrosine kinase inhibitor to in renal cell carcinoma. The combination therapy showed a synergistic antitumor effect by activating tumor-specific cytotoxic T cells and inducing it in to the tumor. An appropriate tyrosine kinase inhibitor for combination therapy with imiquimod was sorafenib. Relatively low dose sorafenib was effective. In addition, the combination therapy was safety in animal models.

Research Products

• [Journal Article] Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model (2017)
  • Author(s): Karashima Takashi、Udaka Keiko、Niimura Mayumi、Suzuki Katsuhide、Osakabe Hiroto、Shimamoto Tsutomu、Fukata Satoshi、Inoue Keiji、Kuroda Naoto、Seiki Motoharu、Shuin Taro
  • Journal Title: Oncology Letters Volume: 14 Issue: 1 Pages: 1162-1166
  • DOI: 10.3892/ol.2017.6235
  • Peer Reviewed / Open Access
• [Presentation] 腎癌にたいするイミキモドとチロシンキナーゼ阻害剤の新規併用療法 (2015)
  • Author(s): 辛島尚、宇高恵子、新村真由美、川田千明、井上啓史、黒田直人、清木元治、執印太郎、
  • Organizer: 第53回日本癌治療学会学術集会
  • Place of Presentation: 国立京都国際会館他（京都市）
  • Year and Date: 2015-10-29
• [Presentation] 腎癌にたいするイミダゾキノリン誘導体とチロシンキナーゼ阻害剤の新規併用療法 (2015)
  • Author(s): 辛島尚 宇高恵子 新村真由美 川田千明 鎌田雅行 井上啓史 黒田直人 執印太郎
  • Organizer: 第103回日本泌尿器科学会総会
  • Place of Presentation: 石川県立音楽堂他（金沢市）
  • Year and Date: 2015-04-18
• [Patent(Industrial Property Rights)] 腎細胞がん治療剤 (2016)
  • Inventor(s): 辛島 尚
  • Industrial Property Rights Holder: 辛島 尚
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2012-001595
  • Filing Date: 2016-04-19